Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 1/2022

THE PLASMA LEVEL OF SOLUBLE ENDOGLIN IN HYPERTENSIVE PATIENTS UNDERGOING LONG-TERM TREATMENT WITH CANDESARTAN

VALENTINA BUDA 1,2,#, MINODORA ANDOR 3,#, ANCA TUDOR 3*, OCTAVIAN CREȚU 3, CARMEN CRISTESCU 1, CORINA DANCIU 1,2, IONUT LEDEȚI 1,4, ZORIN CRAINICEANU 3,
MIRCEA ONEL 5, DIANA AURORA BORDEJEVIC 3, MIRELA CLEOPATRA TOMESCU 3, OANA SUCIU 6, LUCIAN PETRESCU 3,7, DANA EMILIA MAN 3,7

1Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041, Timișoara,
Romania
2Research Center for Pharmaco-Toxicological Evaluation, “Victor Babeș” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041, Timișoara, Romania
3Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041, Timișoara,
Romania
4Advanced Instrumental Screening Centre, “Victor Babeș” University of Medicine and Pharmacy, 2 Eftimie Murgu Square,
300041, Timișoara, Romania
5Faculty of Medicine, “Vasile Goldiș” Western University, 86 Liviu Rebreanu Street, 310045, Arad, Romania
6Department XIV, Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy, 2 Eftimie Murgu Square,
300041, Timișoara, Romania
7Cardiovascular Diseases Institute, 13 Gheorghe Adam Street, 300310, Timișoara, Romania

Download Full Article PDF

Endoglin is a transmembrane glycoprotein involved in regulating endothelial function and homeostasis. We investigated the effect of candesartan compared with that of different regimens of blood pressure (BP)-lowering agents on the plasma level of soluble endoglin (sEng), a biomarker involved directly in endothelial homeostasis. A total of 395 patients were enrolled, of which 129 had normal BP (group A, control group), 133 were hypertensive patients treated with candesartan (8, 16, or 32 mg/day) in monotherapy (group C) and 133 were hypertensive patients treated with different types of antihypertensive agents (beta-blockers, calcium-channel blockers, diuretics) as monotherapy (group B). Classical methods of assessing endothelial damage (flow-mediated dilatation, intima-media thickness) as well as other biochemical parameters and investigations were undertaken. Correlations with the plasma level of sEng were performed. A lower plasma level of sEng was found in patients undergoing long-term BP-lowering treatment with candesartan compared with that in hypertensive patients undergoing longterm treatment with beta-blockers, calcium-channel blockers, or diuretics (p < 0.001). Diastolic BP and the blood urea nitrogen (BUN) levels were protective factors for sEng. The end-diastolic diameter of the left ventricle and neutrophil count were risk factors for soluble endoglin and thus for endothelial dysfunction. By quantifying a glycoprotein involved in endothelial function/homeostasis regulation, sEng, could be a specific biomarker of vascular and cardiac lesions and predict the efficacy of antihypertensive treatment.